A California appeals court is weighing whether Gilead had a responsibility to develop safer HIV drugs to replace older ones with a higher risk of kidney damage and bone fractures.
A federal task force is recommending widespread use of Gilead HIV drugs as preventative measures to those at high risk of exposure.
Gilead and Teva are not liable for antitrust violations which insurers and other drug purchasers said was a "pay-to-delay" scheme designed to illegally maximize the manufacturers' profits.
Nearly 20 plaintiffs have filed a lawsuit against Gilead, saying it failed to warn patients its TDF-based HIV drugs could cause bone and kidney problems.
A jury reached a defense verdict on Tuesday in a patent lawsuit filed by the U.S. government over Gilead's HIV drugs.
A lawsuit filed by two different plaintiffs say they suffered bone density loss due to the side effects of Gilead TDF-based HIV drugs.
A lawsuit filed by 20 plaintiffs claims Gilead held back safer formulations of its HIV drugs in order to maximize profits at the expense of their kidneys and other health…
Gilead knew its HIV drugs carried severe health risks before the first ones were placed on the market, the lawsuit claims.
One drug manufacturer has agreed to pay $10 million to resolve its part in allegations that Gilead and other drug makers conspired to keep HIV medication prices artificially high.
A Gilead TDF lawsuit involving about 80 plaintiffs alleges the drug maker exposed patients unnecessarily to toxic effects of its HIV drugs when it had a safer formulation available.
